Fakhar Singhera

Fakhar Singhera

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in SLAS Technology
Verified
Journal Article
Open access
PDF file
PBPierre Baillargeon
Pierre Baillargeon
KCKervin Coss-Flores
Kervin Coss-Flores
FSFakhar Singhera
Fakhar Singhera
JSJustin Shumate
Justin Shumate
HWHannah Williams
Hannah Williams
LSLouis Scampavia
Louis Scampavia
Microplates are an essential tool used in laboratories for storing research materials and performing assays. Many types of laboratory automation exist that greatly reduce the effort needed to utilize microplates; however, there are cases where the use of such automation is not feasible or practical. In these instances, researchers must work in an environment where liquid handling operations are performed manually with handheld pipetting devices. This type of work is tedious and error-prone as it relies on researchers to manually track a significant amount of metadata, including transfer volumes, plate barcodes, well contents, and well locations. To address this challenge, we have developed an open-source, semiautomated benchtop system that facilitates manual pipetting using visual indicators. This device streamlines the process of identifying the location of wells so that the researcher can perform manual transfers in a more efficient, reliable, and accurate manner. This system utilizes a graphical user interface that allows the user to load worklists and then issues commands to illuminate wells of interest, providing a visual indicator for users to follow in real time. The software and hardware tools utilized for development, along with the implementation techniques used to produce this system, are described within.

1 January 2018 in Talanta
Verified
Journal Article
Closed access
FSFakhar Singhera
Fakhar Singhera
ECEmily Cooper
Emily Cooper
LSLouis Scampavia
Louis Scampavia
TSTimothy Spicer
Timothy Spicer

10 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
FSFakhar Singhera
Fakhar Singhera
JOJustin Overhulse
Justin Overhulse
TLTerrence Lee
Terrence Lee
JKJonathan E. Katz
Jonathan E. Katz
JLJerry Lee
Jerry Lee
Charles McKennaCharles McKenna
Charles McKenna
Oncologic drug development is lengthy (~14 years) and expensive (~1.2 billion USD) with low clinical trial success rates (4.1%). Big data and artificial intelligence (AI) are widely proposed as tools to address these challenges. In this review, we examine the current performance and future potential of big data and AI applied to preclinical discovery and development, clinical trials, and the regulatory approval process. We first examine the data foundation required for effective AI, including data harmonization, data commons, and analytical tools. We then assess preclinical applications spanning target identification, compound-library curation, virtual ligand screening, generative chemical design, and high-throughput and high-content screening. In clinical development, we consider the use of big data and AI for outcome prediction, trial design, external and synthetic control arms, adaptive monitoring, and in silico trials. Finally, we discuss how post-approval electronic health records can generate real-world data and real-world evidence to support drug repurposing and improve future oncology drug discovery. Big data is conventionally characterized by a series of “Vs.” In this review, we have used seven “Vs” spanning descriptive and constraining properties of big data and a singular outcome. We have proposed an eighth, Vernacular, a constraint defined as the combined alignment of data semantics and terminology, data representation, data exchange, and data governance across heterogeneous, independently generated datasets to promote interoperability and combined analysis. Although cancer data exhibit substantial Volume, Velocity, and Variety, they remain distributed across fragmented repositories that often cannot be readily integrated. We conclude with a discussion of tabulated resources currently available for the application of big data and AI to oncologic therapeutics.

25 February 2026 in Analytical Chemistry
Verified
Journal Article
Open access
ASAlexis Scholtz
Alexis Scholtz
JPJack G. Paulson
Jack G. Paulson
AUArmando D. Urbina
Armando D. Urbina
FSFakhar Singhera
Fakhar Singhera
VNVictoria Nuñez
Victoria Nuñez
AAAndrea Armani
Andrea Armani
Magnetic nanoparticles (MNPs) form the foundation of many technologies, frequently serving to purify proteins or cells from a biological sample or to remove environmental contaminants. Their success relies on their magnetic response, which allows them to be easily controlled in a liquid or solution. Therefore, the magnetic susceptibility provides one metric for assessing the suitability of a MNP for a given application. Unfortunately, conventional methods for measuring the magnetic susceptibility relies on instrumentation that characterizes the MNPs as a dry powder. Because MNPs are typically used in suspension, the measured value may be different from their behavior in suspension, thus providing inaccurate readings. Here, we present the design and validation of a magnetophotometer (MAP), an instrument that characterizes the effective magnetic susceptibility of suspended MNPs via differential optical spectroscopy, providing a more relevant measure of MNPs' magnetic properties. As part of this work, we developed a mathematical model to calculate the effective magnetic susceptibility from the MAP data and validated the model using measurements with a range of magnetic nanoparticles, including particles with different material compositions, sizes, architectures, and surface coatings. Finally, we demonstrate that MAP testing is nondestructive by successfully characterizing bioconjugated particles without damaging the bioactivity of the surface bioconjugation, providing a path for in-line quality control assessment.